PF-Atlas › Clinical Trials › NCT06097260

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast for Idiopathic Pulmonary Fibrosis

PLN-74809 · Phase 2

Registry ID
NCT06097260
Phase
Phase 2
Status
Terminated
Drug / intervention
PLN-74809
Sponsor
Pliant Therapeutics, Inc.
Start
2023-11-16
Enrollment
320
Locations
268

About this trial

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).

View NCT06097260 on ClinicalTrials.gov →

Explore related

PLN-74809 — Treatment profileAll PLN-74809 trialsAll IPF trials

Related trials

PLN-74809 — INTEGRIS-IPFPLN-74809 — NCT04072315PLN-74809 — NCT04396756PLN-74809 — NCT05621252
Medical disclaimer. This page summarizes public trial data for NCT06097260 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.